Pamela Murphy

Pam Murphy has spent the past 25 years building emerging biotechnology companies. She is well-recognized for her ability to improve a company’s access to capital and people, and preserve its corporate reputation during times of crisis and extreme market volatility.

Most recently, as VP Corporate Communication & Investor Relations of Incyte, she played an important role in significantly improving Incyte’s corporate reputation and market capitalization as evidenced by the fact Incyte’s stock price was in the low single digits when she joined the comapny in 2003 and was well above $80 when she retired in April 2015. As importantly, Incyte’s top-tier analyst coverage and core instituional shareholder base have been in place since 2005.

In additon to securing excellent relationships with the investment community, she developed and managed a number of multi-disciplined marketing and communications plans that led to equally strong relationships with other key target audiences for early stage biotech companies including investigators, patient advocacy groups, patients, corporate partners and the media.

Pam is a candid and tenacious team player who is known for a clear focus on the needs of patients and good business outcomes for all. While officially retired from Incyte, and happily focused on becoming a competitive dressage rider, she continues to serve on the Board of Directors for Delaware Bio and provides strategic counsel to emerging life science companies regarding the value of a great reputation.